Search results

Filter (9 in use)

Type 2 selected

Status 3 selected

Last updated

Guidance programme 4 selected

1831 results

Date Relevance

  1. Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

    Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

    Technology appraisal guidance
    Published
    View recommendations

  2. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

    Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults

    Technology appraisal guidance
    Published
    View recommendations

  3. Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

    Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

    Technology appraisal guidance
    Published
    View recommendations

  4. Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

    Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a

    Technology appraisal guidance
    Published
    View recommendations

  5. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

    Evidence-based recommendations on dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant/intolerant chronic myeloid leukaemia in adults

    Technology appraisal guidance
    Published
    View recommendations

  6. Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults

    Technology appraisal guidance
    Published
    View recommendations

  8. Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

    Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)

    Technology appraisal guidance
    Published
    View recommendations

  9. Percutaneous insertion of craniocaudal expandable implants for vertebral compression fracture (IPG568)

    Evidence-based recommendations on percutaneous insertion of craniocaudal expandable implants for vertebral compression fracture in adults

    Interventional procedures guidance
    Published
    View recommendations

  10. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity (IPG569)

    Evidence-based recommendations on single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity

    Interventional procedures guidance
    Published
    View recommendations

  12. Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

    Evidence-based recommendations on dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes in adults

    Technology appraisal guidance
    Last updated
    View recommendations

  18. Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

    Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for unresectable or metastatic melanoma in adults with a BRAF V600

    Technology appraisal guidance
    Published
    View recommendations

  19. Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)

    Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor

    Technology appraisal guidance
    Published
    View recommendations

  20. Single-incision short sling mesh insertion for stress urinary incontinence in women (IPG566)

    Evidence-based recommendations on single-incision short sling mesh insertion for stress urinary incontinence in women

    Interventional procedures guidance
    Published
    View recommendations

  21. Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)

    Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (NSCLC) in adults

    Technology appraisal guidance
    Published
    View recommendations

  22. Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)

    Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing

    Technology appraisal guidance
    Published
    View recommendations

  24. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

    Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion

    Technology appraisal guidance
    Published
    View recommendations

  26. Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy

    Technology appraisal guidance
    Published
    View recommendations

  27. Miniature lens system implantation for advanced age-related macular degeneration (IPG565)

    Evidence-based recommendations on miniature lens system implantation for advanced age-related macular degeneration. This involves implanting an artificial lens

    Interventional procedures guidance
    Published
    View recommendations

  28. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

    Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases

    Technology appraisal guidance
    Published
    View recommendations

  30. Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

    Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had

    Technology appraisal guidance
    Published
    View recommendations

  31. Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)

    Evidence-based recommendations on ramucirumab (Cyramza) for treating previously treated locally advanced or metastatic non-small-cell lung cancer

    Technology appraisal guidance
    Published
    View recommendations

  32. Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

    Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases

    Technology appraisal guidance
    Published
    View recommendations

  33. Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

    Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults

    Technology appraisal guidance
    Published
    View recommendations

  34. Extracorporeal carbon dioxide removal for acute respiratory failure (IPG564)

    Evidence-based recommendations on extracorporeal carbon dioxide removal for acute respiratory failure in adults. This involves reducing the level of carbon

    Interventional procedures guidance
    Published
    View recommendations

  35. Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)

    Evidence-based recommendations on cabazitaxel (Jevtana) for prostate cancer that has come back after it was treated with docetaxel

    Technology appraisal guidance
    Last updated
    View recommendations

  36. Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults

    Technology appraisal guidance
    Published
    View recommendations

  37. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    Evidence-based recommendations on lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del

    Technology appraisal guidance
    Published
    View recommendations

  38. Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)

    Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia (AML) with more than 30% bone marrow blasts

    Technology appraisal guidance
    Published
    View recommendations

  39. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

    Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults

    Technology appraisal guidance
    Last updated
    View recommendations

  40. Percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation (IPG563)

    Evidence-based recommendations on percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation in adults. This involves destroying the

    Interventional procedures guidance
    Published
    View recommendations

  41. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)

    Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a

    Technology appraisal guidance
    Last updated
    View recommendations

  42. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

    Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged

    Highly specialised technologies guidance
    Published
    View recommendations

  43. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

    Evidence-based recommendations on adalimumab (Humira) for treating moderate to severe hidradenitis suppurativa (HS) (acne inversa)

    Technology appraisal guidance
    Published
    View recommendations

  44. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

    Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

    Technology appraisal guidance
    Published
    View recommendations

  45. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

    Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

    Technology appraisal guidance
    Published
    View recommendations

  46. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397)

    Evidence-based recommendations on belimumab (Benlysta) as an add-on treatment for active autoantibody-positive systemic lupus erythematosus

    Technology appraisal guidance
    Published
    View recommendations

  47. Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)

    Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for adults with unresectable or metastatic melanoma that has a BRAF V600

    Technology appraisal guidance
    Published
    View recommendations

  48. Microstructural scaffold (patch) insertion without autologous cell implantation for repairing symptomatic chondral knee defects (IPG560)

    Evidence-based recommendations on microstructural scaffold (patch) insertion without autologous cell implantation for repairing symptomatic chondral knee

    Interventional procedures guidance
    Published
    View recommendations

  49. Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting (IPG561)

    Evidence-based recommendations on transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting

    Interventional procedures guidance
    Published
    View recommendations

  50. Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules (IPG562)

    Evidence-based recommendations on ultrasound-guided percutaneous radiofrequency ablation for treating benign thyroid nodules in adults

    Interventional procedures guidance
    Published
    View recommendations